Daniel A. Guthy

Daniel A. Guthy

Auto-generated profile, based on publicly available information

Daniel A. Guthy

Novartis Biomedical Research, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ELEdwige Lorthiois
Edwige Lorthiois
MGMarc Gerspacher
Marc Gerspacher
KBKim S. Beyer
Kim S. Beyer
AVAndrea Vaupel
Andrea Vaupel
CLCatherine Leblanc
Catherine Leblanc
SCSimona Cotesta
Simona Cotesta

7 May 2025 in Nature
Verified
Journal Article
Open access
PDF file
ZHZachary J. Hauseman
Zachary J. Hauseman
FSFrédéric Stauffer
Frédéric Stauffer
KBKim S. Beyer
Kim S. Beyer
SMSandra Mollé
Sandra Mollé
ECElena Cavicchioli
Elena Cavicchioli
LTLuca Tordella
Luca Tordella
Activating mutations in the rat sarcoma (RAS) genes HRAS, NRAS and KRAS collectively represent the most frequent oncogenic driver in human cancer1. They have previously been considered undruggable, but advances in the past few years have led to the clinical development of agents that target KRAS(G12C) and KRAS(G12D) mutants, yielding promises of therapeutic responses at tolerated doses2. However, clinical agents that selectively target NRAS(Q61*) mutants (* represents ‘any’), the second-most-frequent oncogenic driver in melanoma, are still lacking. Here we identify SHOC2, a component of the SHOC2–MRAS–PP1C complex, as a dependency of RAS(Q61*) tumours in a nucleotide-state-dependent and isoform-agnostic manner. Mechanistically, we found that oncogenic NRAS(Q61R) forms a direct interaction with SHOC2, evidenced by X-ray co-crystal structure. In vitro high-throughput screening enabled the discovery of small molecules that bind to SHOC2 and disrupt the interaction with NRAS(Q61*). Structure-based optimization led to a cellularly active tool compound that shows inhibition of mitogen-activated protein kinase (MAPK) signalling and proliferation in RAS-mutant cancer models, most notably in NRAS(Q61*) settings. These findings provide evidence for a neomorph SHOC2–(canonical)RAS protein interaction that is pharmacologically actionable and relevant to cancer sustenance. Overall, this work provides the concept validation and foundation for developing new therapies at the core of the RAS signalling pathway.

24 January 2024 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
AZAlan Zhang
Alan Zhang
KSKatherine Seiss
Katherine Seiss
LLLaurent Laborde
Laurent Laborde
SPSebastian Palacio-Ramirez
Sebastian Palacio-Ramirez
DGDaniel Guthy
Daniel Guthy
MBMatthew T. Burger
Matthew T. Burger

10 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BBBalázs Budai
Balázs Budai
AVAndrea Vaupel
Andrea Vaupel
CDCallum J. Dickson
Callum J. Dickson
KBKim S. Beyer
Kim S. Beyer
DGDaniel A. Guthy
Daniel A. Guthy
VEVeronika Ehmke
Veronika Ehmke

2 December 2025 in Nature Communications
Verified
Journal Article
Open access
KBKim S. Beyer
Kim S. Beyer
JKJessica Klein
Jessica Klein
SKStéphanie Katz
Stéphanie Katz
PWPatrick Welker
Patrick Welker
MLMylene Lanter
Mylene Lanter
SMSauveur-Michel Maira
Sauveur-Michel Maira
RAS proteins control cell proliferation and activating mutations are collectively the most frequent oncogenic event observed in cancer patients, justifying investments into multiple drug discovery efforts. While RAS-directed therapeutic agents targeting either the inactive GDP-bound or the active GTP-bound state have entered the clinic, invariably resistance is observed. Mutations at drug binding sites represent a common resistance mechanism indicating the need to discover new targetable pockets in RAS. Such efforts are hindered by the small globular size of the protein, for long considered undruggable. Here we perform macrocyclic peptides mRNA and nanobody yeast display screens and discover a targetable ligand-induced pocket in RAS. In vitro and cellular experiments with the KM12 and KM12-AM nanobodies show RAS inhibition via displacement of cRAF, by affecting their protein-protein interaction via the less studied cRAF CRD domain. Further, we provide orthogonal functional validation for the discovered binding pocket via mutagenesis experiments. Notably, the discovered RAS-targeting approach enables simultaneous targeting of both GTP-bound active and GDP-bound inactive states and leaves the SwII pocket unaltered, opening possibilities of combinatorial approaches with clinically approved SwII pocket inhibitors.

1 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
ZHZachary J. Hauseman
Zachary J. Hauseman
FSFrédéric Stauffer
Frédéric Stauffer
KBKim S. Beyer
Kim S. Beyer
SMSandra Mollé
Sandra Mollé
ECElena Cavicchioli
Elena Cavicchioli
LTLuca Tordella
Luca Tordella